• Dennis Rosenberg has been named VP of marketing for Bacchus Vascular (Santa Clara, California). Most recently, Rosenberg was VP of marketing and international sales for VNUS Medical Technologies. Bacchus manufactures devices used by interventional radiologists and vascular surgeons for the minimally invasive treatment of deep vein thrombosis and other peripheral vascular disease.
  • Tush Nikollaj has been named president/CEO of CardioMag Imaging (Albany, New York). Nikollaj was founder of Internet service provider Logical Net. CardioMag makes non-invasive devices to identify patients with coronary artery disease and other cardiovascular conditions.
  • Patricia Knipper, RN, has been named VP of global marketing development for Coherex Medical (Salt Lake City). Knipper previously worked at the Cardiovascular Research Foundation. Coherex focuses on structural heart disease and related conditions.
  • Seth Fischer has been named company group chairman and worldwide franchise chairman of Cordis (New Brunswick, New Jersey), effective Jan. 1. Fischer is currently company group chairman, North America pharmaceuticals, at Johnson & Johnson, parent company of Cordis, a role he assumed in July 2004. Cordis specializes in interventional vascular technology.
  • Christopher Barys was named senior vice president of sales for FlowCardia (Sunnyvale, California). Barys served as VP of sales and marketing for the peripheral vascular systems business of Edwards Lifesciences. FlowCardia manufactures endovascular devices for coronary and peripheral chronic total occlusion recanalization.
  • Thomas Glover has been named CEO of Myomo (Boston). He previously was president/CEO of Vasomedical. Myomo makes non-invasive medical devices.
  • Osiris Therapeutics (Columbia, Maryland) said that Cary Claiborne, its CFO, has left the company to pursue new professional opportunities. Claiborne will provide transition assistance to Osiris through March 31, 2008. Phil Jacoby, corporate controller and assistant secretary, will serve as interim CFO and corporate secretary until Claiborne's successor is named. Jacoby joined Osiris in April 2005 and has more than 20 years of experience in public company finance. Osiris is a stem cell company focused on making products to treat inflammatory, orthopedic and cardiovascular conditions.
  • Bozena Korczak, PhD, has been named VP of drug development for PolyMedix (Radnor, Pennsylvania). Korczak was previously VP of R&D at Cytochroma. PolyMedix is an emerging biotech company developing acute-care products for infectious diseases and acute cardiovascular disorders, based on biomimetics.
  • TherOx (Irvine, California) reported that Shelley Thunen has been named CFO. Most recently, Thunen served as executive VP and CFO of IntraLase. TherOx is focused on developing its Supersaturated Oxygen Therapy that is designed to salvage heart muscle in acute heart attack patients.